Daiichi Sankyo, AstraZenca, Summit Partner To Evaluate Datroway Plus Ivonescimab

Daiichi Sankyo and AstraZeneca entered a clinical-trial collaboration with Summit Therapeutics to evaluate Datroway (datopotamab deruxtecan) combined with ivonescimab across multiple solid tumors, including lung and breast cancers. The agreement expands clinical development of the oncology assets, though the article provides no efficacy data, financial terms, or timeline.